๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

Standards for trials of therapy in inflammatory bowel disease

โœ Scribed by Dr. L. R. Sutherland; S. Hanauer; J. Scholmerich

Publisher
John Wiley and Sons
Year
1997
Tongue
English
Weight
724 KB
Volume
3
Category
Article
ISSN
1078-0998

No coin nor oath required. For personal study only.

๐Ÿ“œ SIMILAR VOLUMES

Optimizing thiopurine therapy in inflamm
Optimizing thiopurine therapy in inflammatory bowel disease
โœ Jean-Baptiste Chevaux; Laurent Peyrin-Biroulet; Miles P. Sparrow ๐Ÿ“‚ Article ๐Ÿ“… 2011 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 113 KB

Despite recent advances, the therapeutic armamentarium for inflammatory bowel disease (IBD) is still limited. In addition, a step-up approach is recommended for most IBD patients. Thus, optimizing each medical therapy before switching to another drug class is the rule in clinical practice. Conventio

Mycophenolate mofetil therapy for refrac
Mycophenolate mofetil therapy for refractory inflammatory bowel disease
โœ S. Palaniappan; A. C. Ford; D. Greer; S. M. Everett; D. M. Chalmers; A. T. R. Ax ๐Ÿ“‚ Article ๐Ÿ“… 2007 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 78 KB

Background: Mycophenolate mofetil (MMF) is an immunomodulatory drug, and its use in inflammatory bowel disease has previously been reported. The aim of this study was to review the Leeds Colitis Clinic experience of the safety and efficacy of MMF in treating patients with refractory Crohn's disease

Medical therapy for children with inflam
Medical therapy for children with inflammatory bowel disease
โœ Dr. Harland Winter; Richard Grand ๐Ÿ“‚ Article ๐Ÿ“… 1996 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 660 KB

About 30% of individuals with inflammatory bowel disease present before the age of 21 years (1). Despite this prevalence, most therapeutic agents are tested in adults with inflammatory bowel disease and pharmacokinetics, safety, and efficacy may never be studied in children and adolescents. In this

Historical antecedents of inflammatory b
Historical antecedents of inflammatory bowel disease therapy
โœ Dr. Joseph B. Kirsner ๐Ÿ“‚ Article ๐Ÿ“… 1996 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 985 KB

The increasingly "scientific" approach to the treatment of inflammatory bowel disease (IBD), that is, therapeutic interventions based on research, for example, in the development of anti-inflammatory agents to suppress pro-inflammatory molecules, is in sharp contrast to the arbitrary and sometimes b